Aclaris Therapeutics Inc.
Topical treatment for benign but aesthetically bothersome growths
This article was originally published in Start Up
Aclaris Therapeutics Inc. is developing a topical treatment for seborrheic keratosis, a type of benign growth typically described as a cross between a lesion and a tumor. As envisioned, the preparation that the company now calls A-101 might not only provide an alternative to surgery, but also may be straightforward enough to be applied by non-physician staff.
You may also be interested in...
Keeping Track: Xermelo, Odactra, Noctiva Approved; Second Submissions For Avelumab And Deutetrabenazine
The latest drug development news and highlights from our US FDA Performance Tracker.
Unique market dynamics and plenty of exit options are attracting investors to dermatology. Profiles of Aclaris Therapeutics, Alexar Therapeutics, Rogne Bioscience, and Scioderm.
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.